Berlin-based neurotech startup Nuuron raises €3.5 million in an oversubscribed seed round led by HTGF, with IBB Ventures and others, to develop a digital drug for Alzheimer's based on retinal neuromodulation.
Aignostics raises $34 million in Series B financing led by ATHOS, with investments from Mayo Clinic, HTGF, and existing investors including IBB Ventures, to expand its AI pathology offerings and enter the U.S. market.
